Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

Abstract

Nivolumab monotherapy provided durable responses and was well tolerated as a third- or later-line treatment for recurrent SCLC. These results suggest that nivolumab monotherapy is an effective third- or later-line treatment for this patient population.